biotechnology

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May ExhibitionsAnbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to…

2 days ago
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

April 16, 2025 08:00 ET  | Source: Nautilus Biotechnology Inc. SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc.…

1 month ago
Anbio Biotechnology AnnouncesClosing of Initial Public OfferingAnbio Biotechnology AnnouncesClosing of Initial Public Offering

Anbio Biotechnology AnnouncesClosing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company…

3 months ago
Anbio Biotechnology Announces Pricing of Initial Public OfferingAnbio Biotechnology Announces Pricing of Initial Public Offering

Anbio Biotechnology Announces Pricing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company…

3 months ago
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDASiren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its…

6 months ago